Before the opening bell, Singlepoint, Inc. (OTC: SING) kicked off the new year by voicing its support for an ongoing congressional push calling for banking reform as it relates to the burgeoning legal cannabis industry.
Marijuana Industry
ChineseInvestors.com, Inc. (CIIX) Sets Goal of Greater than 100% Gain in FY2018 Revenues
ChineseInvestors.com, Inc. (OTCQB: CIIX) recorded a skyrocketing 76% year-over-year operating revenues increase for its fiscal year ended May 31, 2017.
Canopy Growth Corp.: Does Profitability Really Matter Right Now?
Shares of Canopy Growth Corp. (TSX:WEED) took a dip after reporting underwhelming fourth-quarter results that clearly didn’t impress the general public. Although the company saw Q4 revenue soar 191% year over year to $14.7 million, many analysts were looking for revenue to grow to at least $16.4 million. But that is not really a problem.
SinglePoint, Inc. (SING) Maximizes Upside Potential and Limits Downside Risk
SinglePoint, Inc. (OTC: SING), a publicly traded holding company, offers just such non-traditional upside opportunity with its foray into the burgeoning cannabis market.
Alzheimer’s Disease: Cannabis Formulation Shows Promise
Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy.
Is Smoking Cannabis the Key to a Happier, Better Life?
The studies show that consumers of marijuana tend to make more money, spend more time in the great outdoors, devote more of their time to volunteering and have a generally higher amount of happiness in their lives when compared to people who do not use cannabis. This begs the question, is marijuana the key to happiness?
For ChineseInvestors.com, Inc. (CIIX) Beauty is more than Just Skin Deep
ChineseInvestors.com, Inc. (OTCQB: CIIX) is launching a line of hemp-infused skin care products in China. The cannabinoid content of the line makes these products more than just cosmetics.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Tech Discussed at “Cannabis in the Capital Markets” Event
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), through its proprietary technology for delivering bioactive compounds in lipid formulations, offers licensed partners the ability to include cannabidiol (CBD) in a variety of ingestible products appropriate for medical patients and recreational users alike.
Cannabis Sector Strategies Light the Way for Industry Growth
The broader cannabis industry is budding with potential, and the lineup of innovators in this global market provides investors a diverse array of investment opportunities.
Biosynthesis Technology Could Transform Cannabinoid Production
The upward trajectory of the cannabis industry has garnered comparisons to the Internet boom of the early 2000s, as North American sales are on pace to record a compound annual growth rate of 25 percent through 2021, according to Arcview Market Research (1).
Singlepoint, Inc. (SING) CEO Discusses Cannabis Industry Game Plan in Interview with CFN Media Group
Before the opening bell, CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announced the release of an exclusive interview with Singlepoint, Inc. (OTC: SING) CEO Greg Lambrecht.
Rapidly Changing Cannabis Industry Offers Plenty of Growth in Horizontal Markets
From Main Street to Wall Street, the cannabis industry is branching out into a variety of business opportunities for not only the key players involved but smaller startup firms as well.
Farmers Race to Plant Industrial Hemp Across North Carolina
Hemp, Inc. (OTC PINK: HEMP) executives announced today that North Carolina farmers are picking up the pace in planting what they believe will be the next cash crop... industrial hemp.
CanniMed Therapeutics Inc. Reports Financial Results for Q3 2017
CanniMed Therapeutics Inc. (TSX:CMED)today released its financial results for the three and nine months ended July 31, 2017. Highlights Sales of $4.8 million in the quarter were 80 per cent higher than in the comparable period of the prior year and were 29 per cent higher than the second quarter of 2017.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology
If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind.